Chronic Hepatitis News

The FDA announced revisions to the Viread label to include use in pediatric patients aged 2 years to less than 12 years with chronic hepatitis B based on 48-week safety and efficacy data.

This year at The Liver Meeting, data presented on hepatitis C treatment highlighted continued significantly positive outcomes from direct-acting antiviral therapy, reduced rates of hepatocellular carcinoma, and improved outreach and screening techniques.

Sovaldi-based therapy was safe and effective in as short as 8 weeks for treating hepatitis C in patients with cancer and may induce remission of non-Hodgkin’s lymphoma, according to a recently published study.

Antios Therapeutics completed a $25 million oversubscribed Series A financing to develop ATI-2173, an oral drug candidate for treating patients with hepatitis B and potentially coinfected with hepatitis D, according to a press release.

On-treatment improvement of MELD scores correlated with reduced risk for all-cause mortality and hepatic events among patients with chronic hepatitis B and cirrhosis, according to a recently published study.

Treatment with either pegylated interferon with ribavirin or direct-acting antivirals for hepatitis C correlated with a significantly lower risk for cardiovascular disease, especially among patients who achieved sustained virologic response, according to a study published in Gastroenterology.

Mavyret demonstrated 97% sustained virologic response in a large, real-world cohort of patients with hepatitis C over an 8-week course and extended 12-week to 16-week courses, according to recently published data.

The Medicines Patent Pool signed a royalty-free license agreement with AbbVie to enable quality-assured manufacturers to develop and sell generic medicines including Mavyret, according to a press release.

Results from a retrospective review of patients infected with hepatitis C in childhood revealed that those with perinatal infection developed cirrhosis earlier than other risk groups, according to a recently published study.

SAN FRANCISCO — In this exclusive video perspective from The Liver Meeting 2018, Monica Konerman, MD, director of the Michigan Medicine NAFLD Clinic, discusses results of a study that found opioid use to be twice as common among patients with chronic liver disease compared with other common chronic diseases.